Clone and Expression of Human ETA

Abstract

Abstract: It was to facilitate inhibitor screening of endothelin receptor, cloning of human endothelin receptor gene ETA, construction of eukaryotic expression vectors and transient expression of pTag-Lite SNAP-ETA in CHO-K1 cells. Method Human ETA gene fragment were amplified from human lung cancer cell line A549 via RT-PCR and inserted into pTag-Lite SNAP plasmid, the recombinant plasmids were then transiently transfected into CHO-K1 cells using FuGENE? HD, expression of ETA was observed via fluorescence microscope. Result Sequencing result showed pTag-Lite SNAP-ETA expression vector were correctly constructed. Fluorescence microscope images indicated that two vectors were expressed in CHO-K1 cells.

Pan Xiaofei, Shi Lili, Tan Chubing, Lü Chaojun, Xu Weiren, Tang Lida,. Clone and Expression of Human ETA[J]. Biotechnology Bulletin, 2014, 0(2): 187-192.

References

[1] Kappers MH, Van esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating Endothelin-1 levels[J]. Hypertension, 2010, 56（4）：675-681.
[2] Widyantoro B, Emoto N, Nakayama K, et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition[J]. Circulation, 2010, 121（22）：2407-2418.
[3] Eric TW. Endothelium-derived endothelin-1[J/OL]. Pflügers Archiv - European Journal of Physiology, 2010, 459（6）：951-958.
[4] Reriani M, Raichlin E, Prasad A, et al. Long-Term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis[J]. Circulation, 2010, 122（10）：958-966.
[5] Kohan D. Endothelin, hypertension, and chronic kidney disease：new insights[J]. Current Opinion in Nephrology and Hypertension, 2010, 19（2）：134-139.
[6] Dhaun N, Macintyre IM, Melville V, et al. Blood pressure–independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease[J]. Hypertension, 2009, 54（1）：113-119.
[7] Bagnato ARosano L. The endothelin axis in cancer[J/OL]. Int J Biochem Cell Biol, 2008, 40（8）：1443-1451.
[8] Bagnato A, Loizidou M, Pflug B R, et al. Role of the endothelin axis and its antagonists in the treatment of cancer[J]. British Journal of Pharmacology, 2011, 163（2）：220-233.
[9] Ergul A. Endothelin-1 and diabetic complications：Focus on the vasculature[J]. Pharmacological Research, 2011, 63（6）：477-482.
[10] Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells[J]. Current Vascular Pharmacology, 2007, 5（1）：45-52.
[11] Masaki T. Historical review：Endothelin[J]. TRENDS in Pharmacological Sciences, 2004, 25（4）：221-224.
[12] Yanagisawa M, Masashi B. Endothelin 20 years from discovery to therapy[J]. Can J Physiol Pharmacol, 2008, 86（8）：485-498.
[13] Watts SW. Endothelin receptors：what's new and what do we need to know?[J]. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 2010, 298（2）：R254-R260.
[14] Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease[J]. Annu Rev Pharmacool Toxicol, 2007, 47（0）：731-759.
[15] Maclean MR, Mcculloch KM, Baird M. Endothelin ETA-and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles[J]. J Cardiovasc Pharmacol, 1994, 23（5）：838-845.
[16] 张希洲.内皮素受体研究新进展[J].国外医学：创伤与外科基本问题分册, 1998, 19（4）：193-199.
[17] Atsushi Y. Recent advances and future perspectives in therapeutic strategies for pulmonary[J]. Journal of Cardiology, 2012, 60（5）：344-349.
[18] Lewis R, Tomas P, Richard C, et al. Effect of macitentan on morbi-dity and mortality in pulmonary arterial hypertension（pah）：res-ults from the seraphin trial[J]. CHEST Journal, 2012, 142（4）：1026A.
[19] Patricia NS, Giersbergen PV, Halabi A, et al. Macitentan entry-into-humans study with a new endothelin[J]. European Journal of Clinical Pharmacology, 2011, 67（10）：977-984.
[20] Maurel D, Comps-agrar L, Brock C, et al. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies：application to GPCR oligomerization[J]. Nat Methods, 2008, 5（6）：561-567.